TG Therapeutics Inc (TGTX) support and resistance · P/E 18, rev $240.3M
TG Therapeutics Inc (TGTX) is a biotechnology company listed on NASDAQ.
This page maps TG Therapeutics Inc (TGTX) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported TGTX revenue for 2026-06-30 was $240.3M. Net income was $7.8M. Revenue was up 17.3% from 2026-03-31 to 2026-06-30. TGTX currently screens at market cap $7.88B and trailing P/E 18.0.
TGTX currently screens at market cap $7.88B and trailing P/E 18.0. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new TGTX 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the TGTX quote page for the session range and the stock page for the full model.
Not investment advice.